Literature DB >> 24277025

Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates.

David R Snydman1, Laura A McDermott, Nilda V Jacobus.   

Abstract

We evaluated in vitro activity of ceftolozane-tazobactam (TOL-TAZ), formerly CXA-201, against recent clinical anaerobic isolates with emphasis on the Bacteroides fragilis group. Ceftolozane-tazobactam showed good activity against B. fragilis species and intermediate to limited activity against other species of Bacteroides. Ceftolozane-tazobactam showed very good activity against Prevotella spp., Fusobacterium spp., and Propionibacterium spp., varying activities against Gram-positive cocci, and limited activity against Clostridium spp.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24277025      PMCID： PMC3910869          DOI： 10.1128/AAC.02253-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae.

Authors:  Emilia Titelman; Inga M Karlsson; Yigong Ge; Christian G Giske
Journal:  Diagn Microbiol Infect Dis       Date:  2011-05       Impact factor: 2.803

2.  In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.

Authors:  Catharine C Bulik; Henry Christensen; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2009-11-16       Impact factor: 5.191

3.  Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009.

Authors:  D R Snydman; N V Jacobus; L A McDermott; Y Golan; E J C Goldstein; L Harrell; S Jenkins; D Newton; C Pierson; J Rosenblatt; R Venezia; S L Gorbach; A M Queenan; D W Hecht
Journal:  Anaerobe       Date:  2011-06-02       Impact factor: 3.331

4.  Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes.

Authors:  Helio S Sader; Paul R Rhomberg; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2011-02-14       Impact factor: 5.191

5.  Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.

Authors:  Bartolome Moya; Laura Zamorano; Carlos Juan; José L Pérez; Yigong Ge; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

6.  National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.

Authors:  D R Snydman; N V Jacobus; L A McDermott; R Ruthazer; Y Golan; E J C Goldstein; S M Finegold; L J Harrell; D W Hecht; S G Jenkins; C Pierson; R Venezia; V Yu; J Rihs; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

7.  Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).

Authors:  David R Snydman; Nilda V Jacobus; Laura A McDermott; Yoav Golan; David W Hecht; Ellie J C Goldstein; Lizzie Harrell; Stephen Jenkins; Duane Newton; Carl Pierson; John D Rihs; Victor L Yu; Richard Venezia; Sydney M Finegold; Jon E Rosenblatt; Sherwood L Gorbach
Journal:  Clin Infect Dis       Date:  2010-01-01       Impact factor: 9.079
  7 in total
  18 in total

1.  Ceftolozane-tazobactam activity against phylogenetically diverse Clostridium difficile strains.

Authors:  Mark D Gonzalez; Meghan A Wallace; Tiffany Hink; Erik R Dubberke; Carey-Ann D Burnham
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

Review 2.  Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players.

Authors:  Young R Lee; Danni McMahan; Catherine McCall; Gregory K Perry
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

3.  Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.

Authors:  Christopher Lucasti; Ellie Hershberger; Benjamin Miller; Sara Yankelev; Judith Steenbergen; Ian Friedland; Joseph Solomkin
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

4.  Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice.

Authors:  M J Melchers; E Mavridou; S Seyedmousavi; A C van Mil; C Lagarde; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

Review 5.  New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

Review 6.  β-lactam/β-lactamase inhibitor combinations: an update.

Authors:  Kamaleddin H M E Tehrani; Nathaniel I Martin
Journal:  Medchemcomm       Date:  2018-08-17       Impact factor: 3.597

Review 7.  Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2016-02       Impact factor: 9.546

8.  Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.

Authors:  Alberto Hernández-Tejedor; Carmen Débora Merino-Vega; Alfredo Martín-Vivas; Rafael Ruiz de Luna-González; Alberto Delgado-Iribarren; Ángeles Gabán-Díez; Ignacio Temprano-Gómez; Natalia de la Calle-Pedrosa; Ana Isabel González-Jiménez; Alejandro Algora-Weber
Journal:  Infection       Date:  2016-09-26       Impact factor: 3.553

Review 9.  Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.

Authors:  David van Duin; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2016-04-20       Impact factor: 9.079

10.  Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications.

Authors:  Seetha M Tamma; Alice J Hsu; Pranita D Tamma
Journal:  Paediatr Drugs       Date:  2016-02       Impact factor: 3.022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.